An investigation on the anti-tumor properties of FSH33-53-Lytic
详细信息 查看全文
- 作者：Ping Liu ; Runlin Yang ; Donghui Pan…
- 关键词：FSHR ; Lytic ; Anti ; tumor ; MicroPET imaging ; Drug evaluation
- 刊名：Journal of Radioanalytical and Nuclear Chemistry
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：307
- 期：1
- 页码：89-97
- 全文大小：1,004 KB
- 参考文献：1.Smith LL, Brown K, Carthew P, Lim CK, Martin EA, Styles J, White IN (2000) Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit Rev Toxicol 30:571–594CrossRef
2.Munshi A, McDonnell TJ, Meyn RE (2002) Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 50:46–52CrossRef
3.Boman HG (1995) Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13:61–92CrossRef
4.Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389–395CrossRef
5.Hancock RE, Diamond G (2000) The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8:402–410CrossRef
6.Dennison SR, Whittaker M, Harris F, Phoenix DA (2006) Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci 7:487–499CrossRef
7.Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062–3066
8.Papo N, Braunstein A, Eshhar Z, Shai Y (2004) Suppression of human prostate tumor growth in mice by a cytolytic d -, l -amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64:5779–5786CrossRef
9.Oren Z, Hong J, Shai Y (1997) A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. J Biol Chem 272:14643–14649CrossRef
10.Papo N, Shai Y (2003) New lytic peptides based on the d , l -amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42:9346–9354CrossRef
11.Kawamoto M, Horibe T, Kohno M, Kawakami K (2011) A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11:359CrossRef
12.Kawamoto M, Horibe T, Kohno M, Kawakami K (2013) HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo. Mol Cancer Ther 12:384–393CrossRef
13.Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, Matsuzaki K, Kawakami K (2011) A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 47:773–783CrossRef
14.Ueyama H, Horibe T, Nakajima O, Ohara K, Kohno M, Kawakami K (2011) Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer. Biochem Biophys Res Commun 414:60–66CrossRef
15.Sprengel R, Braun T, Nikolics K, Segaloff DL, Seeburg PH (1990) The testicular receptor for follicle stimulating hormone: structure and functional expression of cloned cDNA. Mol Endocrinol 4:525–530CrossRef
16.Simoni M, Gromoll J, Nieschlag E (1997) The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 18:739–773
17.Vu Hai MT, Lescop P, Loosfelt H, Ghinea N (2004) Receptor-mediated transcytosis of follicle-stimulating hormone through the rat testicular microvasculature. Biol Cell 96:133–144CrossRef
18.Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, Cheng MJ, Sun H, Xu CJ (2009) Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69:6506–6514CrossRef
19.Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L (2006) Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 175:2072–2077CrossRef
20.Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621–1630CrossRef
21.Gartrell BA, Tsao CK, Galsky MD (2013) The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies. Urol Oncol 3:1403–1407CrossRef
22.Agris PF, Guenther RH, Sierzputowska-Gracz H, Easter L, Smith W, Hardin CC, Santa-Coloma TA, Crabb JW, Reichert LE Jr (1992) Solution structure of a synthetic peptide corresponding to a receptor binding region of FSH (hFSH-beta 33-53). J Protein Chem 11:495–507CrossRef
23.Westhoff WE, Slootstra JW, Puijk WC, van Leeuwen L, Schaaper WM, Oonk HB, Meloen RH (1997) In vitro inhibition of the biological activity of follicle-stimulating hormone by anti-peptide antisera representing the human follicle-stimulating hormone beta subunit sequence 33–53. Biol Reprod 56:460–468CrossRef
24.Xu YP, Pan DH, Zhu C, Xu Q, Wang LZ, Chen F, Yang RL, Luo SN, Yang M, Yan Y (2014) Pilot study of a novel 18F-labeled FSHR probe for tumor imaging. Mol Imaging Biol 16:578–585CrossRef
25.Xu YP, Pan DH, Wang LZ, Chen F, Luo SN, Yang M (2013) 68Ga-Labeled FSHR antagonist for prostate cancer imaging. Eur J Nucl Med Mol Imaging 40:s282–s283
26.Xu YP, Pan DH, Xu Q, Zhu C, Wang L, Chen F, Yang RL, Luo SN, Yang M (2014) Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe 18F-FBEM-Cys-exendin-4. J Cancer Res Clin Oncol 9:1479–1488CrossRef
27.Wan WX, Guo NK, Pan DH, Yu CJ, Weng Y, Luo SN, Ding H, Xu YP, Wang LZ, Lang LX, Xie QG, Yang M, Chen XY (2013) First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 54:691–698CrossRef
28.Pan DH, Yan YJ, Yang RH, Xu YP, Chen F, Wang LZ, Luo SN, Yang M (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol Imaging 9:342–348CrossRef
29.Lien S, Lowman HB (2003) Therapeutic peptides. Trends Biotechnol 21:556–562CrossRef
30.Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I, Hokfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A (2006) The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 12:636–641CrossRef
31.Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43CrossRef
32.Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, Lobel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP (2006) Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66:811–821CrossRef
33.Wan MF, Feng L, Mei JH, Jiang MY, Hong ZL (2010) Expression and significance of follocle-stimulating hormone receptor in prostate cancer. Chin J Cancer Prev Treat 17:843–846
34.Modi DA, Sunoqrot S, Bugno J, Lantvit DD, Hong S, Burdette JE (2014) Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells. Nanoscale 6:2812–2820CrossRef
35.Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P (1998) Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35:212–220CrossRef
36.Rozell TG, Davis DP, Chai Y, Segaloff DL (1998) Association of gonadotropin receptor precursors with the protein folding chaperone calnexin. Endocrinology 139:1588–1593
37.Wagner CC, Langer O (2011) Approaches using molecular imaging technology—use of PET in clinical microdose studies. Adv Drug Deliv Rev 63:539–546CrossRef
38.Yang M, Gao HK, Yan YJ, Sun XL, Chen K, Quan QM, Lang LX, Kiesewetter D, Niu G, Chen XY (2011) PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 38:1237–1247CrossRef
39.Yang M, Gao HK, Sun XL, Yan YJ, Quan QM, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X (2011) Multiplexed PET probes for imaging breast cancer early response to VEGF121/rGel treatment. Mol Pharm 8:621–628CrossRef
40.Wagner CC, Muller M, Lappin G, Langer O (2008) Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 11:104–110
41.Fischman AJ, Alpert NM, Babich JW, Rubin RH (1997) The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 29:923–956CrossRef - 作者单位：Ping Liu (1)
Runlin Yang (2)
Donghui Pan (2)
Yuping Xu (2)
Chen Zhu (3)
Qing Xu (3)
Lizhen Wang (2)
Junjie Yan (2)
Xiaotian Li (1)
Min Yang (1) (2) (3)
1. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, 450000, China
2. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China
3. Department of Radiation Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China - 刊物类别：Chemistry and Materials Science
- 刊物主题：Chemistry
Nuclear Chemistry
Physical Chemistry
Nuclear Physics, Heavy Ions and Hadrons
Diagnostic Radiology
Inorganic Chemistry - 出版者：Akad茅miai Kiad贸, co-published with Springer Science+Business Media B.V., Formerly Kluwer Academic
- ISSN：1588-2780
文摘
A new designed hybrid peptide FSH33-53-Lytic was synthesized and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor cell membranes disintegration. Through in vitro and vivo study, no significant enhancement on anti-tumor activity was shown compared with Lytic peptide only. We also prepared 18F-Al-NOTA-MAL-FSH33-53-Lytic and use microPET image to observe the FSHR targeting of FSH33-53-Lytic. No accumulation in the tumor may explain the failure of FSH33-53-Lytic on cancer therapy. In summary, microPET image can provide more accurate and visible information for screening new anti-tumor agents.